News & Updates
Filter by Specialty:

Dupilumab mends skin barrier in children with AD, but with caveat
Use of dupilumab results in normalization of stratum corneum (SC) lipids, which is responsible for skin barrier function, in children with atopic dermatitis (AD) within 1 to 2 months of treatment, according to a study presented at AAAAI 2024.
Dupilumab mends skin barrier in children with AD, but with caveat
19 Mar 2024
Trifarotene clears acne battle scars
Individuals dealing with the stubborn scars and hyperpigmentation left behind by acne may find benefit in trifarotene cream – the newest among the new generation of topical retinoids approved for acne treatment, according to the findings of two vehicle-controlled, phase IV studies presented at AAD 2024.
Trifarotene clears acne battle scars
18 Mar 2024
Apremilast improves symptoms, QoL in patients with genital psoriasis
Treatment with apremilast results in a significant reduction in genital psoriasis (G-PsO), as well as improvements in itch, pain, discomfort, redness, and quality of life (QoL), in patients with moderate-to-severe G-PsO who are intolerant to topical therapies, a study has shown.
Apremilast improves symptoms, QoL in patients with genital psoriasis
15 Mar 2024
OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies
Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.